(duplicate) modafinil in hypercapnic respiratory failure
Research type
Research Study
Full title
A pilot study of the use of oral modafinil added to standard care in hypercapnic respiratory failure in COPD
IRAS ID
168201
Contact name
Veronica Varney
Contact email
Sponsor organisation
Epsom and St Helier University Hospitals NHS Trust
Eudract number
2013-005107-13
Clinicaltrials.gov Identifier
017/2014 SMED/D6, R&D number
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Type 2 respiratory failure is common in advanced COPD and is usually treated by nasal ventilation. Not all patients requiring such ventilation can tolerate it with anxiety and phobia influencing their reaction along with treatments failure.
We have treated such patients (who were at risk of death) with oral Modafinil 200mg tablets used off licence as a respiratory stimulant, which led to discharge, improved arterial blood gases and offset further admissions with type 2 respiratory failure. Due to the growing numbers of patients admitted to the NHS each day with this condition we now wish to test our "Proof of concept" in this pilot study. This will be the first study of modafinil in COPD. We propose to select 50 patients with chronic hypercapnic respiratory and openly randomise to oral modafinil 200mg mane or standard care. We will assess their responses at 10 and 40 days at which point the study will end.REC name
London - Surrey Borders Research Ethics Committee
REC reference
14/LO/2225
Date of REC Opinion
27 Jan 2015
REC opinion
Further Information Favourable Opinion